HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis

Histopathology

Volumn 60, Issue 4, 2012, Pages 547-553

  Mccluggage, W Glenn ^a   Connolly, Lynette E ^a   Mcbride, Hilary A ^a   Kalloger, Steve ^b   Gilks, C Blake ^b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

HMGA2; Immunohistochemistry; Serous carcinoma; Uterus

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL INTRAEPITHELIAL CARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TISSUE SECTION; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

ADULT; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; UTERUS;

EID: 84857371041     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04105.x     Document Type: Article

References (34)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 15; 10-17.
2. Yemelyanova A, Ji H, Shih IM et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial, endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009; 33; 1504-1514.
3. Chiesa-Vottero AG, Malpica A, Deavers MT et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int. J. Gynecol. Pathol. 2007; 26; 328-333.
4. Mhawech-Fauceglia P, Herrmann FR, Rai H et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 2010; 133; 899-908.
5. Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 2008; 32; 304-315.
6. Garg K, Leitao MM Jr, Wynveen CA et al. p53 expression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod. Pathol. 2010; 23; 80-92.
7. Reid-Nicholson M, Iyengar P, Hummer AJ et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006; 19; 1091-1100.
8. McCluggage WG. A critical appraisal of the value of immunohistochemistry in diagnosis of uterine neoplasms. Adv. Anat. Pathol. 2004; 11; 162-171.
9. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology 2009; 55; 478-482.
10. Mahajan A, Liu Z, Gellert L et al. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod. Pathol. 2010; 23; 673-681.
11. Wei JJ, Wu J, Luan C et al. HMGA2: a potential biomarker complement to p53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am. J. Surg. Pathol. 2010; 34; 18-26.
12. Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 2010; 29; 343-350.
13. Gattas GJ, Quade BJ, Nowak RA et al. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosom. Cancer 1999; 25; 316-322.
14. Rogalla P, Drechsler K, Frey G et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am. J. Pathol. 1996; 149; 775-779.
15. Reeves R. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ. Health Perspect. 2000; 108; 803-809.
16. Malek A, Bakhidze E, Noske A et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int. J. Cancer 2008; 123; 348-356.
17. Welsh JB, Zarrinkar PP, Sapinoso LM et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl Acad. Sci. USA 2001; 98; 1176-1181.
18. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: distinctive lesion specifically associated with tumors displaying serous differentiation. Hum. Pathol. 1995; 26; 1260-1267.
19. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of five cases including two associated with tamoxifen therapy. Hum. Pathol. 2003; 34; 939-943.
20. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod. Pathol. 1990; 3; 120-128.
21. Goldstein NS, Uzieblo A. WT-1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am. J. Clin. Pathol. 2002; 117; 541-545.
22. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44; 109-115.
23. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int. J. Gynecol. Pathol. 2004; 23; 97-99.
24. Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 2001; 32; 569-577.
25. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010; 221; 49-56.
26. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol. 2006; 13; 1-7.
27. Kindelberger D, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31; 161-169.
28. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007; 211; 26-35.
29. Folkins A, Jarboe E, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 2008; 109; 168-173.
30. Jarboe E, Folkins A, Nucci M et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 2008; 27; 1-9.
31. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53; 127-138.
32. Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J. Pathol. 2010; 220; 5-6.
33. McCluggage WG, Connolly LE, McBride HA. HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma. Am. J. Surg. Pathol. 2010; 34; 1037-1042.
34. Medeiros F, Erickson-Johnson MR, Keeney GL et al. Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower female genital tract. Genes Chromosom. Cancer 2007; 46; 981-990.